17:33 EST TuHURA Biosciences (HURA) files $250M mixed securities shelf
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HURA:
- TuHURA Biosciences Plans Phase 2 Trial for TBS-2025
- TuHURA Biosciences Secures $3M Bridge Loan Agreement
- Tuhura Biosciences Advances in Merkel Cell Carcinoma Treatment Study
- Tuhura Biosciences’ Promising Phase 1 Trial: A Potential Game-Changer in Merkel Cell Carcinoma Treatment
- TuHURA Biosciences Extends Warrant Expiration to 2030